Qian Tianyang, He Yining, Han Chao, Yan Ruxue, He Weiming
Division of Nephrology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.
The First School of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Front Pharmacol. 2025 Jan 14;15:1505206. doi: 10.3389/fphar.2024.1505206. eCollection 2024.
Renal fibrosis is one of the main pathological features of chronic kidney disease (CKD), and its treatment has been a hot research topic. Recent studies have shown that stem cell therapy can repair renal pathological changes and slow the progression of CKD. In addition, a large number of experiments have confirmed that traditional Chinese medicine (TCM), especially Chinese medicine compound preparations, has the advantage of multitargeting interventions to improve renal fibrosis. Therefore, stem cell therapy combined with TCM is expected to provide new therapeutic ideas and measures to solve kidney problems. This article reviews the current status of TCM combined with stem cell therapy for CKD, discusses existing problems, and proposes future prospects.
肾纤维化是慢性肾脏病(CKD)的主要病理特征之一,其治疗一直是研究热点。近期研究表明,干细胞疗法可修复肾脏病理改变并减缓CKD的进展。此外,大量实验证实,传统中医药(TCM),尤其是中药复方制剂,在改善肾纤维化方面具有多靶点干预的优势。因此,干细胞疗法联合中医药有望为解决肾脏问题提供新的治疗思路和措施。本文综述了中医药联合干细胞疗法治疗CKD的现状,探讨了存在的问题,并提出了未来展望。